Literature DB >> 18411237

Effect of low-dose naloxone infusion on fentanyl requirements in critically ill children.

Cindy Maria Darnell1, Jennifer Thompson, Daniel Stromberg, Lonnie Roy, Paul Sheeran.   

Abstract

OBJECTIVE: Sedating critically ill patients often involves prolonged opioid infusions causing opioid tolerance. Naloxone has been hypothesized to limit opioid tolerance by decreasing adenylate cyclase/cyclic adenosine monophosphate activation. The study purpose was to investigate the effect of low-dose naloxone on the maximum cumulative daily fentanyl dose in critically ill children.
METHODS: We conducted a double-blinded, randomized, placebo-control trial from December 2002 through July 2004 in a university PICU. We enrolled 82 children age 1 day to 18 years requiring mechanical ventilation and fentanyl infusions anticipated to last for >4 days were eligible for enrollment. Those receiving additional oral analgesia or sedation, having a history of drug dependence or withdrawal, or having significant neurologic, renal, or hepatic disease were excluded. In addition to fentanyl infusions, patients received low-dose naloxone or placebo infusions. Medications were adjusted using the Modified Motor Activity Assessment Scale. Withdrawal was monitored using the Modified Narcotic Withdrawal Scale. Intervention was a low-dose naloxone infusion (0.25 microg/kg per hour) and the main outcome variable was the maximum cumulative daily fentanyl dose (micrograms per kilogram per day).
RESULTS: There was no difference in the maximum cumulative daily fentanyl dose between patients treated with naloxone (N = 37) or those receiving placebo (N = 35). Adjustment for the starting fentanyl dose also failed to reveal group differences. Total fentanyl dose received throughout the study in the naloxone group (360 microg/kg) versus placebo (223 microg/kg) was not statistically different. Placebo patients trended toward fewer rescue midazolam boluses (10.7 vs 17.8), lower total midazolam dose (11.6 mg/kg vs 23.9 mg/kg), and fewer rescue fentanyl boluses (18.5 vs 23.9).
CONCLUSIONS: We conclude that administration of low-dose naloxone (0.25 microg/kg per hour) does not decrease fentanyl requirements in critically ill, mechanically ventilated children.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411237     DOI: 10.1542/peds.2007-1468

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  Dosing evaluation of continuous intravenous fentanyl infusions in overweight children: a pilot study.

Authors:  Emily C Gish; Donald Harrison; Andrew K Gormley; Peter N Johnson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

2.  The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study.

Authors:  Constance L Monitto; Sabine Kost-Byerly; Elizabeth White; Carlton K K Lee; Michelle A Rudek; Carol Thompson; Myron Yaster
Journal:  Anesth Analg       Date:  2011-09-02       Impact factor: 5.108

Review 3.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

Review 4.  Pharmacological interventions for pain in children and adolescents with life-limiting conditions.

Authors:  Emma Beecham; Bridget Candy; Richard Howard; Renée McCulloch; Jo Laddie; Henrietta Rees; Victoria Vickerstaff; Myra Bluebond-Langner; Louise Jones
Journal:  Cochrane Database Syst Rev       Date:  2015-03-13

5.  Pain assessment during blood collection from sedated and mechanically ventilated children.

Authors:  Layra Viviane Rodrigues Pinto Dantas; Thiago Silveira Pinto Dantas; Valter Joviniano Santana Filho; Isabela Freire Azevedo-Santos; Josimari Melo DeSantana
Journal:  Rev Bras Ter Intensiva       Date:  2016 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.